Marinomed Biotech AG
VSE:MARI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (6.3), the stock would be worth €41.8 (219% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2 | €13.1 |
0%
|
| 3-Year Average | 6.3 | €41.8 |
+219%
|
| 5-Year Average | 8 | €53.5 |
+308%
|
| Country Average | 0.7 | €4.5 |
-66%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
€24.3m
|
/ |
Jul 2025
€11.9m
|
= |
|
|
€24.3m
|
/ |
Dec 2025
€8.7m
|
= |
|
|
€24.3m
|
/ |
Dec 2026
€10.3m
|
= |
|
|
€24.3m
|
/ |
Dec 2027
€12.4m
|
= |
|
|
€24.3m
|
/ |
Dec 2028
€50.8m
|
= |
|
|
€24.3m
|
/ |
Dec 2029
€19.3m
|
= |
|
|
€24.3m
|
/ |
Dec 2030
€24.1m
|
= |
|
|
€24.3m
|
/ |
Dec 2031
€30.1m
|
= |
|
|
€24.3m
|
/ |
Dec 2032
€37.7m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| AT |
M
|
Marinomed Biotech AG
VSE:MARI
|
30.1m EUR | 2 | 4.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 12.3 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 5.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 4.9 | 28.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 4.2 | 15 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 4.9 | 20.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.8 | 11.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 2.4 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 2.4 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.5 |
| Median | 0.7 |
| 70th Percentile | 1.2 |
| Max | 25.7 |
Other Multiples
Marinomed Biotech AG
Glance View
Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. The company is headquartered in Korneuburg, Niederoesterreich and currently employs 43 full-time employees. The company went IPO on 2019-02-01. The firm develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The firm also offers products for the treatment of influenza, combination products for asthmatics, and others. The firm also develops treatments for type I allergies and autoimmune diseases. The firm is a spin-off from the University of Veterinary Medicine, Vienna.
